Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer

Liu, Kaisheng1; Lai, Minshan2,3; Wang, Shaoxiang2; Zheng, Kai2; Xie, Shouxia1; Wang, Xiao1

2020-03-31

10.1155/2020/6107865

Biomed Research International   影响因子和分区

2314-6133

2314-6141

Colon cancer is the third most common cancer, with a high incidence and mortality. Construction of a specific and sensitive prediction model for prognosis is urgently needed. In this study, profiles of patients with colon cancer with clinical and gene expression data were downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (TCGA). CXC chemokines in patients with colon cancer were investigated by differential expression gene analysis, overall survival analysis, receiver operating characteristic analysis, gene set enrichment analysis (GSEA), and weighted gene coexpression network analysis. CXCL1, CXCL2, CXCL3, and CXCL11 were upregulated in patients with colon cancer and significantly correlated with prognosis. The area under curve (AUC) of the multigene forecast model of CXCL1, CXCL11, CXCL2, and CXCL3 was 0.705 in the GSE41258 dataset and 0.624 in TCGA. The prediction model was constructed using the risk score of the multigene model and three clinicopathological risk factors and exhibited 92.6% and 91.8% accuracy in predicting 3-year and 5-year overall survival of patients with colon cancer, respectively. In addition, by GSEA, expression of CXCL1, CXCL11, CXCL2, and CXCL3 was correlated with several signaling pathways, including NOD-like receptor, oxidative phosphorylation, mTORC1, interferon-gamma response, and IL6/JAK/STAT3 pathways. Patients with colon cancer will benefit from this prediction model for prognosis, and this will pave the way to improve the survival rate and optimize treatment for colon cancer.

SCI

英语

第一 ; 通讯

Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis - Cultivating Fund Project of Shenzhen People's Hospital[SYKYPY201928]

Biotechnology & Applied Microbiology ; Research & Experimental Medicine

Biotechnology & Applied Microbiology ; Medicine, Research & Experimental

WOS:000528682200002

HINDAWI LTD

Web of Science

1.Jinan Univ, Clin Med Coll 2, Southern Univ Sci & Technol, Affiliated Hosp 1,Shenzhen Peoples Hosp, Shenzhen, Guangdong, Peoples R China
2.Shenzhen Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Shenzhen, Guangdong, Peoples R China
3.Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou, Peoples R China

Liu, Kaisheng,Lai, Minshan,Wang, Shaoxiang,et al. Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer[J]. Biomed Research International,2020,2020.

Liu, Kaisheng,Lai, Minshan,Wang, Shaoxiang,Zheng, Kai,Xie, Shouxia,&Wang, Xiao.(2020).Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer.Biomed Research International,2020.

Liu, Kaisheng,et al."Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer".Biomed Research International 2020(2020).